Is Major Move Coming For Oxford Immunotec Global PLC (OXFD) After This Wedge Down Pattern?

December 7, 2017 - By Linda Rogers

Investors sentiment decreased to 1.27 in 2017 Q2. Its down 0.56, from 1.83 in 2017Q1. It is negative, as 10 investors sold Oxford Immunotec Global PLC shares while 20 reduced holdings. 8 funds opened positions while 30 raised stakes. 19.91 million shares or 1.07% more from 19.70 million shares in 2017Q1 were reported.
Axa has 894,388 shares. Penn Cap holds 0.22% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 179,415 shares. Polar Cap Limited Liability Partnership reported 2.10 million shares or 0.48% of all its holdings. Commercial Bank Of Montreal Can accumulated 0% or 11,458 shares. Cortina Asset Mngmt Lc holds 0.36% or 499,525 shares in its portfolio. Parkwood Limited Liability holds 0.03% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 12,799 shares. 423,831 were accumulated by Wasatch Advisors Incorporated. Georgia-based Invesco Limited has invested 0.01% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Manufacturers Life Ins Company The reported 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). Geode Cap Mgmt Lc reported 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Royal National Bank Of Canada owns 185 shares. Northwestern Mutual Wealth Mgmt accumulated 193 shares. Wells Fargo And Commerce Mn, California-based fund reported 29,485 shares. New York-based Neuberger Berman Gru Lc has invested 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Blackrock has 1.03 million shares.

Since June 15, 2017, it had 0 insider buys, and 1 sale for $61,305 activity.

The stock of Oxford Immunotec Global PLC (OXFD) formed a down wedge with $13.36 target or 4.00 % below today’s $13.92 share price. The 6 months wedge indicates high risk for the $357.12M company. If the $13.36 price target is reached, the company will be worth $14.28 million less.
Falling wedges are poor performers for bullish breakouts and are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 11% and 15%. The average rise is 32% and the decline is 15%. The falling wedges has high throwback and pullback rate: 56%, 69% and the percent of wedges meeting target is not very high.

The stock decreased 1.90% or $0.27 during the last trading session, reaching $13.92. About 105,114 shares traded. Oxford Immunotec Global PLC (NASDAQ:OXFD) has risen 54.26% since December 8, 2016 and is uptrending. It has outperformed by 37.56% the S&P500.

Analysts await Oxford Immunotec Global PLC (NASDAQ:OXFD) to report earnings on February, 27. They expect $-0.34 EPS, down 54.55 % or $0.12 from last year’s $-0.22 per share. After $-0.24 actual EPS reported by Oxford Immunotec Global PLC for the previous quarter, Wall Street now forecasts 41.67 % negative EPS growth.

Oxford Immunotec Global PLC (NASDAQ:OXFD) Ratings Coverage

Among 4 analysts covering Oxford Immunotec (NASDAQ:OXFD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oxford Immunotec had 8 analyst reports since July 19, 2017 according to SRatingsIntel. The stock has “Buy” rating by Cowen & Co on Wednesday, July 19. The firm earned “Buy” rating on Wednesday, August 16 by Cowen & Co. The company was maintained on Tuesday, October 31 by Robert W. Baird. Cowen & Co maintained the shares of OXFD in report on Wednesday, September 27 with “Buy” rating. BTIG Research initiated Oxford Immunotec Global PLC (NASDAQ:OXFD) on Thursday, September 28 with “Buy” rating. Cowen & Co maintained the stock with “Buy” rating in Tuesday, October 31 report. The stock of Oxford Immunotec Global PLC (NASDAQ:OXFD) earned “Buy” rating by Robert W. Baird on Thursday, October 19.

More notable recent Oxford Immunotec Global PLC (NASDAQ:OXFD) news were published by: which released: “Oxford Immunotec Appoints Richard Wenstrup, MD, as Chief Medical Officer” on July 24, 2017, also with their article: “Oxford Immunotec Announces National Reimbursement for the T-SPOTĀ®.TB Test in …” published on June 22, 2017, published: “Oxford Immunotec Global’s (OXFD) CEO Peter Wrighton-Smith on Q2 2017 Results …” on August 01, 2017. More interesting news about Oxford Immunotec Global PLC (NASDAQ:OXFD) were released by: and their article: “Oxford Immunotec Names Karen Koski Head of Strategy and Investor Relations” published on June 05, 2017 as well as‘s news article titled: “Oxford Immunotec to Present at the Jefferies 2017 London Healthcare Conference” with publication date: November 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: